Frank Löscher
Directeur Général chez Dermaliq Therapeutics, Inc.
Profil
Frank Löscher is currently the President & Chief Executive Officer at Dermaliq Therapeutics, Inc. and the Chief Technology Officer at Novaliq GmbH.
He has an undergraduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate degree from the University of Regensburg.
Postes actifs de Frank Löscher
| Sociétés | Poste | Début |
|---|---|---|
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Directeur Technique/Scientifique/R&D | - |
Dermaliq Therapeutics, Inc.
 Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Directeur Général | - |
Formation de Frank Löscher
| University of Regensburg | Doctorate Degree |
| Ruprecht-Karls-Universität Heidelberg | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Novaliq GmbH
Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Health Technology |
Dermaliq Therapeutics, Inc.
Dermaliq Therapeutics, Inc. Information Technology ServicesTechnology Services Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical company based in Wilmington, DE, USA. Dermaliq has signed a USD 15 million series A round to advance three transformative skin care drug therapies through clinical trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital, and Whale Technology Corporation Ltd. The company was founded in 2021 through a spin-off from Novaliq GmbH to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The CEO of the company is Frank Lösher. | Technology Services |
